Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

Published:2016-11-08 Issue:6 Volume:58 Page:1376-1383
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Finnes Heidi D.¹,Chaffee Kari G.²,Call Timothy G.³,Ding Wei³,Kenderian Saad S.³,Bowen Deborah A.³,Conte Michael³,McCullough Kristen B.¹,Merten Julianna A.¹,Bartoo Gabriel T.¹,Smith Matthew D.¹,Leis Jose⁴,Chanan-Khan Asher⁵,Schwager Susan M.³,Slager Susan L.⁶,Kay Neil E.³,Shanafelt Tait D.³,Parikh Sameer A.³

Affiliation:

1. Department of Pharmacy, Mayo Clinic, Rochester, MN, USA;

2. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA;

3. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

4. Division of Hematology Oncology, Mayo Clinic, Phoenix, AZ, USA;

5. Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL, USA;

6. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1251592

Reference30 articles.

1. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

2. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

3. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

5. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

2. Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia;Anti-Cancer Drugs;2022-08-10

3. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib;Cardio-Oncology;2021-11-19

4. Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib;Expert Review of Clinical Pharmacology;2021-09-20

5. Management of cardiovascular complications of bruton tyrosine kinase inhibitors;British Journal of Haematology;2021-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3